Imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK0787) was compared to moxalactam in a randomized therapeutic trial involving 39 evaluable patients with serious bacterial infections. Of those treated with imipenem, 89% were cured or improved versus 60% for moxalactam (P = 0.06). Although mucocutaneous fungal infections occurred in both groups (25 and 10%, respectively), Streptococcus faecalis superinfection was seen in two patients in the moxalactam group only. Adverse drug reactions occurred with both drugs, although bleeding occurred in three patients treated with moxalactam.
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Imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK0787) is a novel betalactam antibiotic having desthiocarbapenem as its nucleus. In vitro studies (5) suggest that the drug is extremely potent against a wide variety of bacteria. Whereas other new beta-lactam antibiotics such as moxalactam have decreased activity against Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus species and show relatively large inoculum effects on the minimum inhibitory concentrations (MICs) toward Pseudomonas aeruginosa and Enterobacter species, imipenem is relatively free of these problems (1) . Moreover, imipenem retains good activity against Streptococcus faecalis and Bacteroidesfragilis, unlike most other new cephalosporins. To determine the clinical relevance of these promising in vitro data, we undertook a clinical trial comparing imipenem to moxalactam in seriously ill patients with a variety of infections.
MATERIALS AND METHODS
Patients with septicemia, soft tissue, respiratory tract, and urinary tract infections were admitted to a randomized study at The Fairfax Hospital (Falls Church, Va.) comparing moxalactam (2 g intravenously every 8 h) to imipenem (0.5 g intravenously every 6 h) combined with MK0791, a structural analog of imipenem designed to block catabolism of the drug by the brush border of the kidney (6). The method of culturing, laboratory tests for safety, and informed consent have all been described previously (2) , with the exception that Mueller-Hinton broth was used for the determination of MICs rather than Trypticase soy broth (BBL Microbiology Systems). Susceptibility to imipenem and moxalactam was initially determined for all isolates by using 10-,ug disks for imipenem and 30-,ug disks for moxalactam. Zones equal to or greater than 16 and 18 mm, respectively, were used to indicate sensitivity. Although we hoped that all isolates would be sensitive to both antibiotics, in several instances in the imipenem group, bacteria were resistant to moxalactam. One patient who had been started on moxalactam was dropped from the study when her P. aeruginosa isolate was shown to be moxalactam resistant. A second patient who developed a rash after a small dose of imipenem was also dropped from the study. Gramstained specimens were examined for the presence of polymorphonuclear leukocytes and homogeneous populations of organisms (except in polymicrobial infections) in an attempt to distinguish pathogens from colonizers identified on cultures.
Wound infections showed signs of local inflammation with purulent drainage. Intraabdominal infections consisted of abscesses or cholangitis or both. Respiratory tract infections were diagnosed by the presence of purulent sputum or sinus drainage and radiological evidence of infection of the lung or sinus. Urinary tract infections had colony counts greater than 105 per ml of urine with pyuria noted on urinalysis. Septicemia was defined as the occurrence of two or more positive blood cultures.
Cure was defined as the complete resolution of signs of infection accompanied by sterilization of the infected site at the conclusion of therapy. When culture specimens were no longer available, assessment of response was made on clinical grounds alone. Improvement was defined as the subsiding of signs of infection and no need for further surgical or antibiotic therapy. For urinary tract infections, additional cultures were obtained 1 and 4 weeks after therapy. Statistical analysis was performed with the Fisher exact test (two-tailed).
RESULTS
Moxalactam and imipenem were administered to 20 and 21 patients, respectively, utilizing a randomization scheme generated by computer at Merck Sharp & Dohme Research Laboratories.
One case in each group was dropped from the study because they were considered non-evaluable, but they were followed for safety. Of the 39 patients, 25 were males and 14 were females, ranging from 19 to 85 (mean, 46) years of age. The sex and age distribution were similar in each antibiotic group. Duration of therapy was 3 to 28 days, with a mean of 11.2 days in the moxalactam group and 11.9 days in the imipenem group. Of the 39 patients, 21 had serious underlying diseases or conditions (12 in the moxalactam group and 9 in the imipenem group) which would be expected to interfere with the patient's ability to combat infection. These included diabetes mellitus with unstable blood sugars and peripheral vascular disease (six cases), nondiabetic peripheral vascular disease in patients with infections of the lower extremities (three cases), steroid therapy (three cases), cancer (three cases), cystic fibrosis (one case), a Foley catheter in one patient with a urinary tract infection, and four cases of collagen vascular disease (systemic lupus erythematosis, rheumatoid arthritis, giant cell arteritis, and mixed connective tissue disease with nephrotic syndrome). Twenty-nine patients (15 treated with moxalactam and 14 treated with imipenem) had soft tissue infections. These consisted of four intraabdominal infections in each group, three surgical wound infections in each group, five traumatic wound infections (one received moxalactam), and four infected plantar ulcers in diabetic patients (one received moxalactam). Four patients had respiratory tract infections (one in the moxalactam group), four had urinary tract infections (three in the moxalactam group), and two had septicemia (one in each group).
Bacteria cultured initially were comparable in both groups (Table 1 Table 4 ). Colonization of wounds by Enterobacter species was noted at the conclusion of imipenem therapy in two instances.
There was a satisfactory clinical response in 12 of the 20 patients (60%) treated with moxalactam, including 5 who were cured, 7 who were improved, and 8 who failed (Table 2 ). In comparison, 17 of the 19 patients (89%) treated with imipenem responded satisfactorily to the drug (P = 0.06) ( Table 3) . Of these, nine were cured, eight improved, and two failed. Four patients receiving moxalactam and four receiving imipenem had their therapy interrupted by adverse drug reactions. Of these, all four moxalactam patients were clinically improving at the time of discontinuation of drug therapy. Of the four imipenem patients, one was improving at the (3, 4, 7) . At least part of the explanation may lie in the inoculum effect on their MICs in the cases of Pseudomonas, Serratia, and Enterobacter species (1) . In addition, they may have somewhat less activity in treating staphylococcal and streptococcal infections than older cephalosporins (8) . Finally, their somewhat decreased activity against B. fragilis makes them somewhat less attractive in the therapy of intraabdominal abscesses (9) .
When imipenem was compared in this randomized trial with the new oxy-beta-lactam, moxalactam, several possible differences were noted. Therapeutic efficacy (patients cured or improved) was demonstrated in 89% of patients treated with imipenem but in only 60% of those receiving moxalactam (P = 0.06). The moxalactam clinical efficacy rate falls within the 50 to 79% range reported previously (3, 4, 7) . Part of this discrepancy could be explained by the maldistribution of cases of cellulitis (all six received moxalactam), by the slightly higher frequency of underlying diseases in the moxalactam group (60%) compared with the imipenem group (45%), or by the nonblinded nature of the study. With regard to adverse reactions, patients treated with moxalactam showed evidence in three cases of bleeding due to its effect on the prothrombin time as well as perhaps to its inhibition of platelet aggregation (10) . Imipenem appears to be free of this side effect, which can be life threatening in critically ill patients. Although the number of patients was small, rendering statistical analysis somewhat tenuous, imipenem showed a tendency toward superior efficacy, less S. faecalis superinfection, and fewer bleeding abnormalities compared to moxalactam. With its extreme potency against a broader spectrum of bacteria than the thirdgeneration cephalosporins, the temptation may be to employ it widely in patients with serious bacterial infections. However, further studies should be undertaken to confirm the above findings and to determine what the effect of the widespread use of imipenem on the nosocomial flora will be, especially in view of a 25% rate of mucocutaneous candidiasis in this group.
